14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today ATHX ranks #14694 as hold candidate. Get a Free Stock at Robinhood
Stronger Stock

$1.11 (3.74%)

Volume: 2M

Closed: Dec 08, 2021

Hollow Logo Score: -0.110

Athersys Stock Forecast

$1.11 (3.74%)

Volume: 2M

Closed: Dec 08, 2021

Score Hollow Logo -0.110
Which way will ATHX go? Request
Stop-loss: $1.07 (-3.89%)
Key Stats
Beta 1.55
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 47 and the stock is currently not being overbought or oversold

Athersys stock upgraded to Hold/Accumulate.
(Updated on Dec 08, 2021)

Hold candidate since 2021-12-08

The Athersys stock price gained 3.74% on the last trading day (Wednesday, 8th Dec 2021), rising from $1.07 to $1.11. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 7.04% from a day low at $1.07 to a day high of $1.14. The price has been going up and down for this period, and there has been a 8.82% gain for the last 2 weeks. Volume fell on the last day by -112 thousand shares and in total, 2 million shares were bought and sold for approximately $2.29 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -26.96% during the next 3 months and, with a 90% probability hold a price between $0.67 and $0.90 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

There are mixed signals in the stock today. The Athersys stock holds a buy signal from the short-term moving average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term moving average at $1.17. On a fall, the stock will find some support from the short-term average at $1.06. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). A buy signal was issued from a pivot bottom point on Friday, November 19, 2021, and so far it has risen 10.45%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss

Athersys finds support from accumulated volume at $1.06 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.0750 between high and low, or 7.04%. For the last week, the stock has had a daily average volatility of 7.76%.

Our recommended stop-loss: $1.07 (-3.89%) (This stock has high daily movements and this gives high risk. There is a buy signal from a pivot bottom found 12 days ago.)

Is Athersys stock A Buy?

Athersys holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

Current score: -0.110

Predicted Opening Price for Athersys of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$1.11 $1.11 (Overvalued)
Hold/Accumulate Upgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

Needham & Company LLC is very positive about ATHX and gave it a "Buy" rating on Nov 10, 2020. The price target was set to $5.00.

Volatility and Risk
Daily Average Volatility: 7.76 %
Overall Risk: Very High High Medium Low Very Low
7.76 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $1.13
Price: $1.11
Support: $1.06

ATHX Insider Trading Show all Trades



Last 100 transactions
Buy: 22 466 524 | Sell: 903 305 (Shares)
Date Action Amount Person Type
Nov 19, 2021 Buy 85 000 Kola Ismail Common Stock
Nov 17, 2021 Buy 15 000 Macleod Ivor Common Stock
Oct 28, 2021 Sell 5 000 Lehmann William Jr Stock Option (right to purchase)
Oct 28, 2021 Buy 5 000 Lehmann William Jr Common Stock
Sep 20, 2021 Sell 30 000 Lehmann William Jr Common Stock
Show all Insider Trades


Last 100 transactions
Buy: 22 466 524 | Sell: 903 305 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 1.18 6.31 %
1.15 3.73 %
1.13 2.13 %
Current price: 1.11
Support 1.08 -3.03 %
1.06 -4.63 %
1.03 -7.21 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 1.25 12.61 %
1.15 3.60 %
1.13 1.80 %
Current price 1.11
Support 1.06 -4.50%
1.02 -8.11%
1.01 -9.46%

Click to get the best stock tips daily for free!

About Athersys

Athersys Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The company’s lead platform product, MultiStem cell therapy, an allogeneic stem cell product, which is in Phase II clinical trials for the treatment of ischemic stroke and inflammatory bowel disease (IBD); and that has completed Phase I clinical trial for the treatment of acute myocardial infarction and hematopoietic... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE